BioCentury | Dec 31, 2020
Distillery Therapeutics

SIRT5 overexpression could rescue mitochondrial disease induced by SUCLA2 mutations

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Mitochondrial disease Promoting the expression of the desuccinylase SIRT5 could treat a hereditary mitochondrial encephalomyopathy caused by succinyl-CoA ligase deficiency, which is some patients results from mutations in the tricarboxylic acid...
BioCentury | Nov 6, 2018
Distillery Therapeutics

Cancer

...bound an allosteric site on SIRT6 with a K d of 5.4 μM and activated SIRT6...
...in models of other diseases in which SIRT6 is implicated, including neurodegenerative disorders. TARGET/MARKER/PATHWAY: Sirtuin 6 (SIRT6...
...email: chengq@shsmu.edu.cn CONTACT: Jian Zhang, same affiliation as above email: jian.zhang@sjtu.edu.cn Claire Quang Shanghai Jiao Tong University Sirtuin 6 (SIRT6) Liver...
BioCentury | Aug 17, 2018
Company News

Juvenescence, partners form anti-aging biotech

Juvenescence Ltd. (Douglas, Isle of Man), Insilico Medicine Inc. (Baltimore, Md.) and the Buck Institute for Research on Aging (Novato, Calif.) partnered to form anti-aging company Napa Therapeutics Ltd. (Tortola, British Virgin Islands). Napa will...
BioCentury | Aug 14, 2018
Company News

Juvenescence, partners form anti-aging biotech

Juvenescence Ltd. (Douglas, Isle of Man), Insilico Medicine Inc. (Baltimore, Md.) and the Buck Institute for Research on Aging (Novato, Calif.) partnered to form anti-aging company Napa Therapeutics Ltd. (Tortola, British Virgin Islands). Napa will...
BioCentury | Apr 17, 2018
Distillery Therapeutics

Neurology

INDICATION: Neurology Cell culture and mouse studies suggest promoting the expression of SIRT1 could help treat Alzheimer’s disease and other neurodegenerative tauopathies. In HEK cells expressing mutant human tau, plasma vector-encoded SIRT1 decreased levels of...
BioCentury | Jan 31, 2018
Distillery Therapeutics

Cancer

INDICATION: Bone cancer; colorectal cancer Cell culture and mouse studies suggest inhibiting SIRT5-mediated desuccinylation of SHMT2 could help treat osteosarcoma and colorectal cancer. In a human osteosarcoma cell line, knockout of SIRT5 increased levels of...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
BioCentury | Nov 14, 2017
Preclinical News

Hybrid T cells show anticancer effects

A study published in Cell Metabolism by researchers at Medical University of South Carolina and colleagues showed that the enhanced antitumor effect of a hybrid of T helper types 1 (Th1) and 17 (Th17) cells...
BioCentury | Oct 3, 2017
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest activating SIRT7 or promoting its expression could help treat metastatic breast cancer. In samples from metastatic breast cancer patients, levels of SIRT7 were lower...
BioCentury | Jun 27, 2017
Distillery Therapeutics

Autoimmune disease

INDICATION: Osteoarthritis Patient sample and mouse studies suggest inhibiting SIRT1 could help treat osteoarthritis. In cartilage samples from patients, levels of activated DOT1L , a negative regulator of SIRT1, were lower than in samples from non-arthritic...
Items per page:
1 - 10 of 162